Database Release 2023.1

The latest release of the IUPHAR/BPS Guide to Pharmacology database was made on 26th April 2023. This database release is version 2023.1, and is the first release this year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:

  • 3,023 human targets, 1,662 of which have curated quantitative ligand interactions.
  • 11,944 ligands, 8,814 of which have curated quantitative target interactions.
  • 1,872 approved drugs, 1,098 with curated quantitative interactions.
  • Clinical use summaries for over 3,385 ligands of which 1,866 are approved drugs.
  • A total of 19,890 curated binding constants
  • Data curated from over 43,543 references

Curation Update

Updates have been made to many target family summary pages in preparation for generating the 2023-24 issue of the Concise Guide to PHARMACOLOGY (due for publication at the end of the year). More significant modifications have been made to the summary pages for the GABAA receptors (in Ion channels) and Orexin receptors (in GPCRs). A major overhaul of the Taste 2 GPCRs (Bitter taste receptors) has been completed, with newly annotated details for ligands that interact with these receptors. We thank all of our contributors who have given so freely of their time to make these updates possible.

As a regular review of the INN lists from the WHO, we added 31 new kinase inhibitors to the Guide (see table 1), that were included in the Jan 2023 list of proposed INNs (List 128). The chemical structures allowed us to connect around half of these (16/31) INNs to clinical leads (some with declared name>structure), and others to patents from which we could obtain otherwise unpublished target information and interaction data. Five of the structures matched ligands that were already in the Guide. In total we have found interaction data for 27/31 of these inhibitors. For a few, we were unable to track down very little additional information.

31 new kinase inhibitors added to the GtoPdb
Ligand ID INN Name/code Target Ligand ID INN Name/code Target
9131 plixorafenib PLX8394 BRAF 12738 ficonalkib n/a ALK
10094 sofnobrutinib n/a BTK 12379 flizasertib n/a RIPK1
11746 monzosertib AS0141 CDC7 12380 mifanertinib n/a EGFR
12155 zasocitinib NDI-034858 TYK2 12381 resencatinib n/a RET
12319 lartesertib M4076 ATM 12382 risovalisib CYH33 PI3Kα
12357 elenestinib BLU-263 KIT 12383 risvodetinib IkT-148009? Abelson-family tyrosine kinases
12368 boditrectinib AUM601/HL5101 pan-NTRK 12384 rovadicitinib n/a JAK
12369 ifebemtinib BI-853520/IN10018 FAK 12385 tinodasertib AUM001/ETC206 MKNK1/2
12370 lirafugratinib RLY-4008 FGFR 12386 zelasudil n/a ROCK
12371 milrebrutinib AS-1763 BTK 12387 zongertinib BI 1810631? ERBB2
12372 oditrasertib n/a RIPK1 12388 zotizalkib TPX0131 ALK
12373 narmafotinib AMP945 FAK 12389 zurletrectinib n/a NTRK
12374 pumecitinib PG-011? JAK 12390 nimucitinib n/a JAKs
12375 adrixetinib n/a AXL, MER, CSF1R 12391 vabametkib n/a MET
12376 darizmetinib HRX-0215? MKK4 12392 zidesamtinib NVL-520 ROS1
12377 emzeltrectinib n/a NTRK


A new set of antivirals for SARS-CoV-2 have been curated, based on patent extractions by our collaborator Chris Southan:

example I-1 [WO2023283831] (12588), TBK845 (12589), example 18 [WO2022013684] (12590), GDI-036 (12591), example 45 [WO2022229458] (12592) and compound 6 [WO2022133588] (12593) are Mpro inhibitors, and PLpro inhibitor 7 (12596) inhibits the other crucial coronavirus protease PLpro. New to this list of antivirals are two PROTAC class protein degraders, both of which target the Mpro for proteosomal degradation; these are CoV Mpro CRBN PROTAC 9 [US11530195] (21594) and CoV Mpro VHL PROTAC 9 [US11518759] (12595).

Keeping up with drug approvals for 2023, there have been 14 new drugs approved by the  FDA since the beginning of the year. The table below provides the ligand IDs for the 11/14 that are curated in the Guide.

14 new drugs approved by FDA in 2023. 11 added to the GtoPdb have ID in first column
Ligand ID INN Trade name Type FDA Approval date Indication EMA approval date
12202 lecanemab Leqembi mAb 06/01/2023 To treat Alzheimer’s disease n/a
12335 bexagliflozin Brenzavvy sm 20/01/2023 To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise n/a
11628 pirtobrutinib Jaypirca sm 27/01/2023 To treat mantle cell lymphoma n/a
12339 elacestrant Orserdu sm 27/01/2023 To treat advanced/metastatic ER-positive, HER2-negative, ESR1 mutated breast cancer n/a
8455 daprodustat Jesduvroq sm 01/02/2023 To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months n/a
n/a velmanase alfa-tycv Lamzede pep 16/02/2023 To treat non-central nervous system manifestations of alpha-mannosidosis 23/03/2018
8448 sparsentan Filspari sm 17/02/2023 To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression n/a
n/a efanesoctocog alfa Altuviiio Fc fusion peptide 23/02/2023 Routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and children with hemophilia A n/a
7573 omaveloxolone Skyclarys sm 28/02/2023 To treat Friedreich’s ataxia in adults and adolescents aged 16 years and older n/a
11513 zavegepant Zavzpret sm 10/03/2023 To treat migraine with or without aura in adults n/a
12482 trofinetide Daybue pep 13/03/2023 To treat Rett syndrome n/a
11583 retifanlimab Zynyz mAb 22/03/2023 To treat metastatic or recurrent locally advanced Merkel cell carcinoma n/a
n/a rezafungin Rezzayo sm 22/03/2023 To treat candidemia and invasive candidiasis n/a
9424 leniolisib Joenja sm 24/03/2023 To treat activated phosphoinositide 3-kinase delta syndrome (APDS) n/a

Antibacterial Curation

We are pleased to report that the Global Antibiotic Research and Development Partnership (GARDP; has extended their funding of our collaboration with Antibiotic DB (ADB; for a further 2 years. Through this interaction, GtoPdb provides chemistry and pharmacology for a curated set of antibacterial compounds with links to ADB.

Currently we have 425 ligands tagged in GtoPdb as ‘antibacterial’ and 413 of these have links to compounds at ADB. The antibacterials in the GtoPdb include approved drugs, WHO essential Medicines-listed medicines and a number of investigational and experimental compounds.

Web-Application & Database Update

We have updated the version of ChEMBL used on the website. This is now at ChEMBL version 32. On the Guide to Pharmacology website we use data from ChEMBL to supplement both our pharmacology search and ligand activity charts.

We have updated our PubChem CID outlinks – updating ~380 links some of which had been to deprecated CIDs.

We have also done a check and update of our Ensembl out-links, updating deprecated ID/links in a number of cases.


Posted in Chemical curation, Database updates, Technical

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: